NeuroSense Therapeutics Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NRSN research report →
Price Chart
About the company
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS).
- CEO
- Alon Ben-Noon
- IPO
- 2021
- Employees
- 17
- HQ
- Herzliya, TA, IL
Get TickerSpark's AI analysis on NRSN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $12.39M
- P/E
- -0.79
- Fwd P/E
- 0.21
- PEG
- -0.59
- P/S
- 0.00
- P/B
- -5.74
- EV/EBITDA
- -1.12
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 1070.23%
- ROIC
- 797.48%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-11,085,000
- Net Income
- $-11,125,000-9.0%
- EPS
- $-0.44+20.0%
- OCF Growth
- +24.3%
- FCF Growth
- +24.3%
- 52W High
- $1.98
- 52W Low
- $0.25
- 50D MA
- $0.63
- 200D MA
- $0.82
- Beta
- 1.60
- RSI (14)
- 22
- Avg Volume
- 256.95K
No earnings-call transcripts are available for NRSN yet.
- Free Float
- 66.0%
- Shares Outstanding
- 35.35M
- Float Shares
- 23.32M
of shares held by institutions
13 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | Ben-Noon Alon | buy | 250,000 |
| Jun 16, 26 | Eisenberg Or | buy | 250,000 |
| Mar 26, 26 | Eisenberg Or | other | 200,000 |
| Mar 18, 26 | Eisenberg Or | other | 0 |
| Mar 18, 26 | Eisenberg Or | other | 0 |
| Mar 18, 26 | Eisenberg Or | other | 0 |
| Jul 1, 21 | Eisenberg Or | other | 21,000 |
| Aug 15, 24 | Eisenberg Or | other | 66,666 |
| Mar 18, 26 | Mandil-Levin Revital | other | 0 |
| Mar 18, 26 | Mandil-Levin Revital | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NRSN coverage
Recent articles, reports, and earnings notes.
No research on NRSN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NRSN report →NeuroSense Issues CEO Letter to Shareholders
prnewswire.com · Aug 13
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
gurufocus.com · Aug 6
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
prnewswire.com · Aug 6
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
prnewswire.com · Jul 22
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
prnewswire.com · Jul 6
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
gurufocus.com · Jun 29
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
prnewswire.com · Jun 29
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
prnewswire.com · Jun 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.